Abstract

PurposeMYCN amplification plays a critical role in defining high-risk subgroup of patients with neuroblastoma. We aimed to develop and validate the CT-based machine learning models for predicting MYCN amplification in pediatric abdominal neuroblastoma.MethodsA total of 172 patients with MYCN amplified (n = 47) and non-amplified (n = 125) were enrolled. The cohort was randomly stratified sampling into training and testing groups. Clinicopathological parameters and radiographic features were selected to construct the clinical predictive model. The regions of interest (ROIs) were segmented on three-phrase CT images to extract first-, second- and higher-order radiomics features. The ICCs, mRMR and LASSO methods were used for dimensionality reduction. The selected features from the training group were used to establish radiomics models using Logistic regression, Support Vector Machine (SVM), Bayes and Random Forest methods. The performance of four different radiomics models was evaluated according to the area under the receiver operator characteristic (ROC) curve (AUC), and then compared by Delong test. The nomogram incorporated of clinicopathological parameters, radiographic features and radiomics signature was developed through multivariate logistic regression. Finally, the predictive performance of the clinical model, radiomics models, and nomogram was evaluated in both training and testing groups.ResultsIn total, 1,218 radiomics features were extracted from the ROIs on three-phrase CT images, and then 14 optimal features, including one original first-order feature and eight wavelet-transformed features and five LoG-transformed features, were identified and selected to construct the radiomics models. In the training group, the AUC of the Logistic, SVM, Bayes and Random Forest model was 0.940, 0.940, 0.780 and 0.927, respectively, and the corresponding AUC in the testing group was 0.909, 0.909, 0.729, 0.851, respectively. There was no significant difference among the Logistic, SVM and Random Forest model, but all better than the Bayes model (p <0.005). The predictive performance of the Logistic radiomics model based on three-phrase is similar to nomogram, but both better than the clinical model and radiomics model based on single venous phase.ConclusionThe CT-based radiomics signature is able to predict MYCN amplification of pediatric abdominal NB with high accuracy based on SVM, Logistic and Random Forest classifiers, while Bayes classifier yields lower predictive performance. When combined with clinical and radiographic qualitative features, the clinics-radiomics nomogram can improve the performance of predicting MYCN amplification.

Highlights

  • Neuroblastoma (NB) is one of the most common solid malignancy in children originating from neural crest tissues along the sympathetic chains [1]

  • MYCN amplification status plays a significant role in risk classification of NBs, and NBs with MYCN amplified are usually classified into the high-risk group, where the patients need intensive treatment of operation, radiotherapy and chemotherapy [19]

  • The results of our study showed that radiomics models based on non-enhanced phase (NP), arterial phase (AP) and venous phase (VP) images can predict MYCN amplification in pediatric abdominal NB, while the performance of different machine learning radiomics models varies

Read more

Summary

Introduction

Neuroblastoma (NB) is one of the most common solid malignancy in children originating from neural crest tissues along the sympathetic chains [1]. As a kind of heterogeneous tumor, the clinical outcome of abdominal NB varies from spontaneous regression to extensive systemic metastasis [3]. Among the various attempts from different international groups aimed to identify factors that can be used to risk stratification and to define an sub-population with poor clinical outcome [6], all groups highlight the significance of MYCN amplification status for defining high-risk group and consider that all patients with MYCN amplified are prone to relapse [2]. The detection of MYCN amplification status is critical to riskstratify patients. The availability of detection of MYCN has been hindered by the limited access to genetic testing methods in many institutions [9], an alternative non-invasive method is needed to characterize the MYCN amplification status availably

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call